4-fluoro-3-iodobenzylamine | 732224-35-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-fluoro-3-iodobenzylamine
• 英文别名: (4-fluoro-3-iodophenyl)methanamine
• CAS: 732224-35-0
• 化学式: C₇H₇FIN
• mdl: MFCD18396954
• 分子量: 251.042
• InChiKey: GEESFURQMNZQQV-UHFFFAOYSA-N

物化性质

• 沸点：
  277.2±30.0 °C(Predicted)
• 密度：
  1.849±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.142
• 拓扑面积：
  26
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  N,N′-二-Boc-硫脲 、 4-fluoro-3-iodobenzylamine 在 三乙胺 、 mercury dichloride 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 5.0h， 以57%的产率得到N,N'-bis(tert-butyloxycarbonyl)-N''-(4-fluoro-3-iodobenzyl)guanidine
  参考文献：
  名称：

  (4-[18F]Fluoro-3-iodobenzyl)guanidine, a Potential MIBG Analog for Positron Emission Tomography

  摘要：

  The aims of this investigation were to develop a no-carrier-added (nea) synthesis of (4-[F-18]-fluoro-3-iodobenzyl)guanidine (F-18]FIBG) and to evaluate its potential as an MIBG analogue useful for positron emission tomography. [F-18]FIBG was prepared in four steps starting from 4-cyano-2-iodo-N,N,N-trimethylanilinium trifluoromethanesulfonate in 5% decay-corrected radiochemical yield in a total synthesis time of 130 min. The specific activity was more than 1500 Ci per mmol. In vitro binding studies showed that the percent binding of [F-18]FIBG to SK-N-SH human neuroblastoma cells remained constant over a 3-log activity range and was similar to that of nca [I-131]MIBG. Specific and high uptake of FIBG was also seen in mouse heart and adrenals. The in vitro and in vivo properties of[F-18]FIBG suggest that this compound may be a useful positron-emitting analogue of MIBG.

  DOI：

  10.1021/jm00047a022
• 作为产物：
  描述：

  4-氟-3-碘苯甲腈 在 硼烷四氢呋喃络合物 作用下， 以 四氢呋喃 为溶剂， 反应 6.0h， 生成 4-fluoro-3-iodobenzylamine
  参考文献：
  名称：

  (4-[18F]Fluoro-3-iodobenzyl)guanidine, a Potential MIBG Analog for Positron Emission Tomography

  摘要：

  The aims of this investigation were to develop a no-carrier-added (nea) synthesis of (4-[F-18]-fluoro-3-iodobenzyl)guanidine (F-18]FIBG) and to evaluate its potential as an MIBG analogue useful for positron emission tomography. [F-18]FIBG was prepared in four steps starting from 4-cyano-2-iodo-N,N,N-trimethylanilinium trifluoromethanesulfonate in 5% decay-corrected radiochemical yield in a total synthesis time of 130 min. The specific activity was more than 1500 Ci per mmol. In vitro binding studies showed that the percent binding of [F-18]FIBG to SK-N-SH human neuroblastoma cells remained constant over a 3-log activity range and was similar to that of nca [I-131]MIBG. Specific and high uptake of FIBG was also seen in mouse heart and adrenals. The in vitro and in vivo properties of[F-18]FIBG suggest that this compound may be a useful positron-emitting analogue of MIBG.

  DOI：

  10.1021/jm00047a022

文献信息

• [EN] HETEROBICYCLIC METALLOPROTEASE INHIBITORS<br/>[FR] INHIBITEURS DE MÉTALLOPROTÉASE HÉTÉROBICYCLIQUES
  申请人：ALANTOS PHARM HOLDING

  公开号：WO2008063671A2

  公开（公告）日：2008-05-29

  [EN] The present invention relates generally to heterobicyclic containing pharmaceutical agents, and in particular, to heterobicyclic metalloprotease inhibitor compounds. More particularly, the present invention provides a new class of heterobicyclic metalloprotease inhibiting compounds that exhibit an increased potency in relation to currently known metalloprotease inhibitors.
  [FR] La présente invention concerne de manière générale des agents pharmaceutiques contenant une matrice hétérobicyclique, et en particulier des composés inhibiteurs de métalloprotéase hétérobicycliques. Plus particulièrement, la présente invention propose une nouvelle catégorie de composés inhibiteurs de métalloprotéase hétérobicycliques qui présentent une activité accrue par rapport aux inhibiteurs de métalloprotéase actuellement connus.